The Molecular Biomedicine Group published in the journal "Frontiers in Pharmacology" a paper entitled „Comprehensive pharmacogenomics profiling of the Serbian population“. 

A new study has mapped how genetic differences in the Serbian population affect drug response, marking a key step toward personalized medicine. Researchers analyzed genetic data from 881 Serbians and found notable variations in genes like CYP2B6, NAT2, SLCO1B1, UGT1A1, and VKORC1—all of which influence how the body processes common drugs, including statins and antidepressants. The study revealed that some of these genetic patterns differ significantly from those in other populations. This means treatments could be better tailored to the Serbian population using genetic testing. Incorporating these findings into routine healthcare could make prescribing more accurate and effective, reducing side effects and improving outcomes. 

This research is part of the dissertation of Marina Jelovac, and it was conducted within the PharmGenHub project, funded by the European Comission within the HORIZON-WIDERA Twinning program, coordinated by Dr. Branka Zukić.